Cookies help us deliver our services. By using our services, you agree to our use of cookies. More information

Difference between revisions of "Nouette-Gaulain 2009 Anesthesiology"

From Bioblast
Line 17: Line 17:
{{Labeling
{{Labeling
|organism=Human, Rat
|organism=Human, Rat
|tissues=Skeletal Muscle, Neurons; Brain
|tissues=Skeletal muscle, Neurons; Brain
|preparations=Intact Cell; Cultured; Primary, Permeabilized Tissue
|preparations=Intact Cell; Cultured; Primary, Permeabilized tissue
|enzymes=Complex I, Complex II; Succinate Dehydrogenase, Complex III, Complex IV; Cytochrome c Oxidase, Complex V; ATP Synthase
|enzymes=Complex I, Complex II; Succinate Dehydrogenase, Complex III, Complex IV; Cytochrome c Oxidase, Complex V; ATP Synthase
|topics=Respiration; OXPHOS; ETS Capacity
|topics=Respiration; OXPHOS; ETS Capacity
|additional=Spectrophotometry; Spectrofluorimetry
|additional=Spectrophotometry; Spectrofluorimetry
}}
}}

Revision as of 01:14, 5 April 2012

Publications in the MiPMap
Nouette-Gaulain K, Bellance N, Prรฉvost B, Passerieux E, Pertuiset C, Galbes O, Smolkova K, Masson F, Miraux S, Delage JP, Letellier T, Rossignol R, Capdevila X, Sztark F (2009) Erythropoietin protects against local anesthetic myotoxicity during continuous regional analgesia. Anesthesiology 110: 648-659.

ยป PMID: 19212263

Nouette-Gaulain K, Bellance N, Prevost B, Passerieux E, Pertuiset C, Galbes O, Smolkova K, Masson F, Miraux S, Delage JP, Letellier T, Rossignol R, Capdevila X, Sztark F (2009) Anesthesiology

Abstract: BACKGROUND: Local anesthetics offer the benefits of extended analgesia with greater patient satisfaction and faster rehabilitation compared with intravenous morphine. These benefits, however, can be offset by adverse iatrogenic muscle pain caused by bupivacaine. Here, the authors describe the mechanisms of local anesthetic-induced myotoxicity and a partial protective effect of recombinant human erythropoietin (rhEPO).

METHODS: The authors developed a rat analgesia model with femoral nerve catheter and a cell culture model of human skeletal muscle myoblasts to study local anesthetic effects. Rats were randomly assigned to four different groups: daily intraperitoneal injection with 5,000 U/kg rhEPO or saline coupled to a perineural catheter injection with 1 ml/kg bupivacaine, 0.25%, or saline. In psoas rat muscle, oxygen consumption rates were measured using a Clark-type electrode in saponin-skinned fibers. Mitochondrial adenosine triphosphate synthesis rates were determined by bioluminescence. Enzymatic activity of mitochondrial respiratory chain complexes was measured on tissue homogenates using spectrophotometric procedures, and mitochondrial morphology was analyzed by transmission electron microscopy. In addition, the interaction between bupivacaine and rhEPO was investigated on human skeletal muscle myoblasts by fluorescence microscopy using mitotracker green and using the lipophilic cation JC-1.

RESULTS: Bupivacaine caused impairment of mitochondrial structure and bioenergetics in rats. Human myoblasts treated with bupivacaine showed a dose-dependent decrease in mitochondrial membrane potential associated with unusual morphologies. Impairment of mitochondrial bioenergetics was prevented partially by the use of rhEPO coadministered with bupivacaine.

CONCLUSIONS: The authors demonstrated a dose- and time-dependent protective effect of rhEPO against bupivacaine-induced myotoxicity in regional analgesia. โ€ข Keywords: Recombinant human erythropoietin (rhEPO), Analgesia, Mitochondria, Local anesthetic

โ€ข O2k-Network Lab: CZ_Prague_Jezek P, FR_Bordeaux_Rossignol R, FR_Bordeaux_Letellier T


Labels:


Organism: Human, Rat  Tissue;cell: Skeletal muscle, Neurons; Brain"Neurons; Brain" is not in the list (Heart, Skeletal muscle, Nervous system, Liver, Kidney, Lung;gill, Islet cell;pancreas;thymus, Endothelial;epithelial;mesothelial cell, Blood cells, Fat, ...) of allowed values for the "Tissue and cell" property.  Preparation: Intact Cell; Cultured; Primary"Intact Cell; Cultured; Primary" is not in the list (Intact organism, Intact organ, Permeabilized cells, Permeabilized tissue, Homogenate, Isolated mitochondria, SMP, Chloroplasts, Enzyme, Oxidase;biochemical oxidation, ...) of allowed values for the "Preparation" property., Permeabilized tissue  Enzyme: Complex I, Complex II; Succinate Dehydrogenase"Complex II; Succinate Dehydrogenase" is not in the list (Adenine nucleotide translocase, Complex I, Complex II;succinate dehydrogenase, Complex III, Complex IV;cytochrome c oxidase, Complex V;ATP synthase, Inner mt-membrane transporter, Marker enzyme, Supercomplex, TCA cycle and matrix dehydrogenases, ...) of allowed values for the "Enzyme" property., Complex III, Complex IV; Cytochrome c Oxidase"Complex IV; Cytochrome c Oxidase" is not in the list (Adenine nucleotide translocase, Complex I, Complex II;succinate dehydrogenase, Complex III, Complex IV;cytochrome c oxidase, Complex V;ATP synthase, Inner mt-membrane transporter, Marker enzyme, Supercomplex, TCA cycle and matrix dehydrogenases, ...) of allowed values for the "Enzyme" property., Complex V; ATP Synthase"Complex V; ATP Synthase" is not in the list (Adenine nucleotide translocase, Complex I, Complex II;succinate dehydrogenase, Complex III, Complex IV;cytochrome c oxidase, Complex V;ATP synthase, Inner mt-membrane transporter, Marker enzyme, Supercomplex, TCA cycle and matrix dehydrogenases, ...) of allowed values for the "Enzyme" property.  Regulation: Respiration; OXPHOS; ETS Capacity"Respiration; OXPHOS; ETS Capacity" is not in the list (Aerobic glycolysis, ADP, ATP, ATP production, AMP, Calcium, Coupling efficiency;uncoupling, Cyt c, Flux control, Inhibitor, ...) of allowed values for the "Respiration and regulation" property. 



Spectrophotometry; Spectrofluorimetry